| TA75 |
Hepatitis C - pegylated interferons, ribavirin and alfa interferon (TA75) |
|
-
-
Interferon alfa and ribavirin for the treatment of chronic hepatitis C - part review of exisiting guidance no.14
This guidance replaces Hepatitis C - alpha interferon and ribavirin (TA14). This guidance is extended by Hepatitis C - peginterferon alfa and ribavirin(TA106).
This guidance has been partially updated by ‘Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C’ (NICE technology appraisal guidance 200). See the guidance and the quick reference guide for more information.
-
Other information
How this guidance was produced
Background information
- Review decision, August 2008
- Review proposal, March 2008
- TA75 Hepatitis C - pegylated interferons, ribavirin and alfa interferon: distribution list
- People with chronic hepatitis C to benefit from guidance on new drugs and treatments
- Health technology assessment: interferon alpha (pegylated and non-pegylated) and ribavirin in the treatment of chronic hepatitis C
This page was last updated: 20 April 2011
-
-
Guidance formats
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- Patient version (PDF)
- TA75 Defnyddio interferon alfa, peginterferon alfa a ribavirin i drin hepatitis C cronig: deall canllawiau NICE
Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Guideline for patients and carers (PDF)
-
Implementation tools and resources
- None available
See this guidance in practice
Patient
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
NICE Guidance
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
Full Guidance
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.
